ADMP, BGFV, ATNX and ESPR among midday movers
- BySeeking Alpha-
Adamis Pharmaceuticals (ADMP): FY cash and equivalents at the end of the year was approximately $6.9 million.Revenue of $16.5M (-25.4% Y/Y) misses by $1.75M.Press Release
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has provided an update on its marketing application's status seeking approval for Zimhi's high-dose naloxone injection product to...
ABIOMED, Inc. (NASDAQ:ABMD) is scheduled to release first-quarter fiscal 2020 results on Aug 1, before market opens. We believe that despite persistent foreign currency woes,...
Masimo Corporation (NASDAQ:MASI) is scheduled to report second-quarter 2019 results on Jul 31, after the closing bell. A slew of developments and product launches are expected to...
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.